Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.

Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.

Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.

And the company might one day follow Galapagos into decentralised manufacturing.

The group claims a seven-day vein-to-vein time is unique, and says why this matters.

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.

A CD22-directed Car that has had several owners will next year deliver its most important dataset.

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.